Heartland
What’s the Difference Between Full-Spectrum vs. Isolate CBD?

When looking for CBD products, you may have noticed that the products usually come in one of two types of CBD: Full Spectrum and Isolate. But what do these mean? What are the differences? And which would be best to choose? Today, I will answer these questions.
WHAT IS FULL SPECTRUM CBD?
Cannabidiol (CBD) is one of the many compounds found in the cannabis plant. Full Spectrum CBD is a product containing not only the cannabidiol but also the many other cannabinoids in the plant. This version is usually minimally refined, leaving the cannabinoids and terpenes intact in the oil.
Full Spectrum is sometimes referred to as “whole-plant” and contains the full plant extract, provided more of the plant’s molecules in ratios, as well as the amounts that nature intended. This is also known as the entourage effect.
These contain THC, but due to regulations, the THC must be kept at a small amount, since this is the compound of cannabis that causes hallucinogenic effects (i.e. gets you high). In the UK, the allowable amount is 0.2 per cent and imported CBD can contain no traces or less than .01 per cent.
Cannabidiol is often used with some terpenes (another cannabis compound that’s found in dozens of other plants, such as lavender, pine, and citrus fruits ) work together to influence each other and overall lead to the benefit of the user. It can help when CBD is used with THC to reduce the effects of a high and influence the user’s cannabinoid receptors.
The full spectrum CBD contains CBD and other cannabinoids as explained below.
-
Cannabinol (CBN)
This variant of cannabinoids has the potential to offer good sedative effects, and research shows they may provide anti-inflammatory and anticonvulsant properties.
-
Cannabigerol (CBG)
This variant of cannabinoids possibly has vital anti-tumour, anti-fungal, and anti-inflammatory properties. It has also shown prospects in the treatment of skin diseases, inflammation, glaucoma, and even cancer.
-
Cannabidivarin (CBDV)
This variant of cannabinoids has potentially anti-nausea, anti-inflammatory, and anti-convulsion properties. They are also very effective in treating mood disorders and reducing pain. They are very effective in relief provision for people suffering from MS, HIV/AIDS, and Crohn’s disease.
-
Cannabichromene (CBC)
This variant of cannabinoids has great anti-cancer, antifungal, anti-depressant, and anti-inflammatory properties.
These are all the potential benefits you will get from the full spectrum and much more. However, opting for the isolate might mean losing some of these important properties completely as they are not available at all in the isolate. For others, it could mean losing some significant quantity of the properties that would have provided better results as opposed to using only the smaller quantities available in the isolate.
With the full spectrum, you will be able to access Vitamin A, Vitamin C, Vitamin E and Vitamin B, protein and essential fats in high quantities. You will also get some quantity of Omega 6 and Omega 3 fatty acids as well as about twenty amino acids. Fatty acids are very beneficial to the health of the heart while amino acids make it possible for the body to produce more protein, thus aiding the time for recovery.
WHAT IS ISOLATE CBD?
CBD Isolate products contain at least 99% pure cannabidiol, with CBD being the only active ingredient. The product has, as the name suggests, isolated down to just the CBD molecule.
The product aims to produce therapeutic doses of CBD, isolated from other cannabinoids and terpenes. These products usually come as a white powder or a mix with a carrier oil for improved absorption. Common carrier oils include vegetable glycerin, olive oil, coconut oil, propylene glycol.
WHICH IS BETTER?
Since Full Spectrum CBD contains different cannabinoids and terpenes, they have the advantage of potentially helping more with your health. Studies found that the effects of full-spectrum CBD on treating inflammatory conditions were superior to isolate CBD. Terpenes alone have shown incredible effects on human health.
However, a CBD Isolate does make it easier to get more CBD, as well as providing assurance of your dosage. Pure CBD has the potential to help treat a multitude of ailments, from diabetes and inflammation to anxiety and depression.
Some people don’t like the taste of hemp extract, so would prefer CBD isolate (or another way of taking CBD like gummies). The flavour may be a reason to mix it in with food or in a cocktail so you don’t have to taste the CBD. Isolate CBD is definitely a better choice for this, as well as personal use for things like massage oil.
Isolate CBD can be more expensive than Full-Spectrum since the process of creating it is more thorough and requires more plant matter to get pure CBD.
Overall, it’s your choice on what type of CBD you choose. Take a look at our extensive collection of CBD
Heartland
The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology
Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects,…

Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects, including memory, pain, reproduction, bone remodeling or immunity, to name a few. Unsurprisingly, given these broad physiological effects, alterations of the ECS have been found in different diseases, including cancer. In recent years, the medical use of cannabis has been approved in different countries for a variety of human conditions. However, the use of these compounds, specifically as anticancer agents, remains controversial. Studies have shown that cannabinoids do have anticancer activity in different tumor types such as breast cancer, melanoma, lymphoma and adult brain cancer. Specifically, phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) has been shown to induce apoptosis and inhibit proliferation of adult cancer cells, as well as modulate angiogenesis and metastasis. Despite increasing evidence that cannabinoids elicit antitumor effects in adult cancers, there is minimal data available on their effects in children or in pediatric cancers despite public and clinical demand for information. Here we describe a comprehensive and critical review of what is known about the effects of cannabinoids on pediatric cancers, highlight current gaps in knowledge and identify the critical issues that need addressing before considering these promising but controversial drugs for use in pediatric oncology.
Keywords: CBD; THC; cannabidiol; cannabinoid; childhood cancer; medical cannabis; pediatric oncology; Δ9-tetrahydrocannabinol.
Heartland
Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment
Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been…

Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB1), type two (CB2), and the G protein-coupled receptor 55 (GPR55)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in Cannabis sp. raw material is also expressed in their increased bioavailability and penetration through the blood-brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in Cannabis extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases.
Keywords: Cannabis; multitarget; phytocannabinoids (THC and CBD); receptors; terpenes.
Heartland
Pervasive cropland in protected areas highlight trade-offs between conservation and food security
Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use…

. 2021 Jan 26;118(4):e2010121118.
doi: 10.1073/pnas.2010121118.
Affiliations
Item in Clipboard
Proc Natl Acad Sci U S A. .
Abstract
Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use our global synthesis cropland dataset to quantify cropland in protected areas globally and assess their relationship to conservation aims and socio-environmental context. We estimate that cropland occupies 1.4 million km2 or 6% of global protected area. Cropland occurs across all protected area management types, with 22% occurring in strictly protected areas. Cropland inside protected areas is more prevalent in countries with higher population density, lower income inequality, and with higher agricultural suitability of protected lands. While this phenomenon is dominant in midnorthern latitudes, areas of cropland in protected areas of the tropics and subtropics may present greater trade-offs due to higher levels of both biodiversity and food insecurity. Although area-based targets are prominent in biodiversity goal-setting, our results show that they can mask persistent anthropogenic land uses detrimental to native ecosystem conservation. To ensure the long-term efficacy of protected areas, post-2020 goal setting must link aims for biodiversity and human health and improve monitoring of conservation outcomes in cropland-impacted protected areas.
Keywords: CBD; area-based targets; conservation; food security; protected areas.
Conflict of interest statement
The authors declare no competing interest.
References
-
- Klein Goldewijk K., Beusen A., Doelman J., Stehfest E.. New anthropogenic land use estimates for the holocene: HYDE 3.2. Earth Syst. Sci. Data. 2017;9:927–953.
-
- Barrett C. B.. Measuring food insecurity. Science. 2010;327:825–828.
-
- Fogel R. W.. The Escape from Hunger and Premature Death, 1700-2100: Europe, America, and the Third World. 2004.
-
- Crist E., Mora C., Engelman R.. The interaction of human population, food production, and biodiversity protection. Science. 2017;356:260–264.
-
- Pimm S. L., Vijay V.. Population, Agriculture, and Biodiversity: Problems and Prospects. 2020;365.
-
News1 week ago
Pure Harvest Bolsters Corporate Team with Key Additions
-
Heartland6 days ago
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
-
Heartland1 week ago
Compared to Prescription Medication, Medical Cannabis Not Always Affordable Alternative
-
Heartland1 week ago
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
-
Heartland1 week ago
Novamind Appoints Chuck Rifici to its Board of Directors
-
Uncategorized1 week ago
Sundial Announces the Launch of Premium Concentrates Products Under its Top Leaf Brand
-
Heartland1 week ago
Can You Treat COVID-19 With CBD and Reduce Mortality Rates? A New Israeli Research Believes You Can!
-
Uncategorized5 days ago
MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors